Agouron Viracept monotherapy shows up to 97% reduction in HIV RNA at four months -- Phase II study.
Executive Summary
AGOURON VIRACEPT MONOTHERAPY SHOWS UP TO 97% DECREASE IN HIV VIRAL LOAD after four months in a randomized Phase II dose-ranging study presented July 9 at the International Conference on AIDS in Vancouver by community-based researcher Marcus Conant, MD, Conant Medical Group, San Francisco. The study was conducted to optimize the dose and regimen for the ongoing Phase II/III trials with the protease inhibitor, which have enrolled 700 patients to date. Agouron has said it expects an NDA filing by the beginning of 1997 ("The Pink Sheet" June 3, T&G-13).